# Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer

> **NCT03025867** · — · APPROVED_FOR_MARKETING · sponsor: **Tesaro, Inc.**

## Conditions studied

- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT03025867
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025867, "Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03025867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*